A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 129 participants.
Also called NCT01280695
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 129 participants
- Sponsor
- Metabolic Solutions Development Company
- Registry
-
NCT01280695
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01280695. Randomized; quadruple masking; primary purpose treatment. Start 2011-02 (registry gives no type); primary completion 2011-06 (actual). Results posted on 2013-12-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- MSDC-0602 100 mg
- Intervention (Drug)
- MSDC-0602 250 mg
- Intervention (Drug)
- MSDC-0602 250 mg
- Intervention (Drug)
- Pioglitazone
- Lead sponsor
- Metabolic Solutions Development Company
Record details
- Record id
cardio:ct-nct01280695- Content hash
48eb380f12bcd00427038d38309b11266426cb43055e6f90f1c51ee177b036f7